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Shine a light 
Aurora Biosciences 
Corporation 
Drug companies are faced with an 
embarrassment of riches these days: 
huge libraries of compounds made 
by combinatorial chemistry, and a 
multitude of new drug targets 
emerging from genome sequencing. 
The science of screening - picking 
out the one compound that matches 
the one target - is now the limiting 
factor. 
The solution appears to be more 
miniaturization and more automation. 
Both of these concepts are part of the 
ultra-high-throughput screening 
system (UHTSS) under development 
at Aurora Biosciences Corporation 
(La Jolla, CA, USA). Aurora is young 
and small, and it is competing with all 
the large pharmaceutical companies, 
which have their own approaches to 
high-throughput screening. But a 
combination of sensitive fluorescent 
detectors, general-purpose screens 
using living cells, and a complex web 
of collaborations could give the 
UHTSS the edge it needs to succeed. 
Divorcing fluorescent couples 
Roger Tsien, of the Howard Hughes 
Medical Institute and University of 
California, San Diego, USA, is one of 
the founders of both Aurora and the 
discipline of fluorescent detector 
engineering. Beginning in 1975, 
Tsien designed a series of synthetic 
calcium detectors including BAPTA, 
fura-2, indo-l and fluo-3. 
Aurora bases its most important 
assay for the UHTSS around a new 
gene expression indicator named 
CCFZ/AM. Although the detailed 
structure of this compound has not 
been disclosed, Aurora’s Chief 
Technical Officer Gordon Foulkes 
says that it consists of two 
fluorophores connected with a 
cephalosporin linker, and esterified 
so that it crosses membranes and is 
trapped inside live cells as the 
polyanion CCFZ. The first 
fluorophore of CCFZ absorbs low 
wavelength (violet) light and would, 
by itself, emit blue light. But if 
CCFE is intact, the excited state 
energy is transferred to the second 
fluorophore and re-emitted as green 
light. This energy relay relies on a 
quantum mechanical effect called 
fluorescence resonance energy 
transfer (FRET), which only works 
over distances of a few nanometers. 
The UHTSS uses live cells with 
a B-lactamase reporter gene. If the 
reporter is active, the B-lactamase 
cleaves the cephalosporin linker and 
the fluorophores are separated. 
FRET no longer occurs, so the 
fluorophores emit more blue light 
and less green light. 
The two parts to the response - 
more blue light and less green light 
- allow the result to be expressed as 
a ratio. This cancels out variability 
caused by unequal loading of 
CCFZ/AM or differing numbers of 
cells, and means that duplicate or 
triplicate assays are unnecessary. 
By simply changing the promoter 
sequence driving the production of 
B-lactamase, the assay can be adapted 
to test for the effectiveness (or, using 
stress-induced promoters, the 
toxicity) of any number of 
therapeutic agents. “We’ve tried to 
create a one-stop shop for screening,” 
says Foulkes. Each new cell line, 
responsive to activation of one of the 
major signal-transduction pathways in 
the cell, is selected using a 
fluorescence-activated cell sorter. 
Assay adaptability is one thing 
that is missing in enzymatic assays, 
which must be customized for each 
new target. Protein-binding assays 
are simpler, but do not differentiate 
between true inhibitors, true 
activators, and inert binders. 
The Aurora assays, says Tsien, do 
that and more: they can target an 
entire pathway, including 
components that are yet to be 
defined. “You may not know which 
macromolecule is best to attack,” he 
explains. “If you are doing an 
enzyme assay, you have to make that 
choice and put all your eggs in that 
one basket.” 
More potential targets does not 
mean more hit compounds. “Cell- 
based assays provide a potentially 
very valuable sieve,” says Tony 
Czarnik of Irori Quantum 
Microchemistry. “If you really have 
access to millions of compounds, 
conventional assays will give you 
more actives than you can deal 
with.” A cell-based assay can filter 
out many of these compounds, 
including those that kill cells, do not 
get into cells, or do not work inside 
cells. Unfortunately, says Czarnik, 
“the sieve is a very inexact one,” and 
results in one cell line may not match 
up with results in another. 
The pathway downstream of 
G-protein-coupled receptors 
(GPCRs) is one of the many 
pathways that can be tested using 
the B-lactamase system. Aurora is 
making such assays generic by using 
the “promiscuous” G proteins (G,,, 
in mice and Car6 in humans) 
discovered by Mel Simon at Caltech. 
These G proteins are activated by a 
wide variety of GPCRs, and so can 
be used to bypass the selectivity of 
the receptor-G-protein interaction. 
A protein of many colors 
With the cloning of the gene for green 
fluorescent protein (GFP) in 1992, 
and the demonstration that it works in 
many different organisms in 1994, 
fluorescence detectlon entered a new 
era. Now the detector was made by 
the cell not the chemist, and it could 
be improved by molecular biology. 
GFP, a product of the Pacific 
Northwest jellyfish Aequonu wictoria, 
is remarkable for at least two reasons. 
First, says Tsien, “it has learned 
to do surgery on its own guts to make 
the chromophore,” the unit of 
fluorescence. After the protein is 
synthesized, a group of three amino 
acids spontaneously cyclizes and 
then is oxidized to yield ap-hydroxy- 
benzylidene imidazolinone group 
with a delocalized pi electron cloud. 
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Figure 1 
Variants of GFP can be used to detect protein 
localization, in this case to the nucleus and 
mitochondria Image courtesy of Rosario 
Rinuto, from Gun Biol. (1996) 6, 183-l 88. 
And second, “the rest of the 
protein forms a rigid shell around the 
chromophore,” says Tsien. This 
means that the light energy that the 
chromophore absorbs is not 
dissipated, but rather is efficiently 
re-emitted as the fluorescent signal. 
But GFP, in its original form, has 
its problems. It takes too long to 
make the chromophore, it is not very 
bright, and it absorbs at two different 
wavelengths, with the lower 
wavelength form isomerizing to the 
higher wavelength form over time. 
Tsien’s lab, including Andrew 
Cubitt and Roger Heim who are now 
both at Aurora, solved all three 
problems to some extent with a 
serine to threonine conversion in the 
chromophore. The new protein 
makes the chromophore more 
rapidly, and only absorbs at the 
higher wavelength, at which it is 
much brighter. Other changes have 
resulted in blue, cyan and yellow 
fluorescent proteins. A number of 
these changes have been patented 
and licensed to Aurora. 
Tsien felt that GFP, although 
-1000 times less sensitive as a 
cellular reporter than the B-lactamase 
system, still had potential. “The aim 
is not just to make it better, it’s to 
teach it a lot of new tricks,” he says. 
The first trick was to make a 
protease sensor by joining the blue 
and green proteins with a 25 amino 
acid linker. GFP itself is resistant to 
proteases, but cleavage of the linker 
disrupts FRET between the two 
proteins. Tsien and Aurora also 
created a GFP kinase sensor, which 
changes its fluorescence upon 
phosphorylation, and with others 
have used GFP to detect protein 
localization (Figure 1) and 
interactions between proteins (using 
two GFP fusions and FRET). 
FRETting over ions 
The B-lactamase and GFP systems 
are not easily adaptable to measuring 
the opening and closing of ion 
channels, and electrodes are 
impractical for high-throughput 
screening. Tsien’s solution to this 
problem, working with Tito 
Gonzalez (also now at Aurora), is 
again based on FRET In this case 
the donor is coumarin linked to the 
membrane lipid phosphatidyl- 
ethanolamine, and the acceptor is a 
synthetic oxonol in the membrane. 
At normal resting potentials FRET 
is efficient, but when the cell is 
depolarized the negatively charged 
oxonol migrates across the bilayer 
while the labeled lipid remains in 
the outer leaflet, thus diminishing 
FRET 
Nanoplates and robotics 
About half of the technical staff at 
Aurora are engineers, a good indicator 
that the machinery is as important as 
the assay methods. In two or three 
years, Aurora aims to have its 
UHTSS fully operational, screening 
100,000 compounds a day using 3456- 
well “nanoplates” that are the same 
size as conventional 96-well plates. 
Each well of a nanoplate only holds 
-1 pl (including tens to hundreds of 
cells). A piezoelectric device delivers 
volumes as small as 200 pl by using 
high frequency voltage pulses to 
create 2000 drops per second. The 
tiny volumes will obviate the need 
for serial dilutions of compounds 
before they are added to assays. 
Packard Instrument Company is 
assisting with the development of the 
nanoplates, the fluid delivery system, 
and a high density, sensitive 
fluorescence detector. 
Aurora is trying to protect every 
component of its system with a series 
of patent applications, which are 
jostling with applications covering 
other systems from other companies. 
According to Czarnik, with no 
screening system established as the 
dominant one,“we’re in the wild 
west right now.” 
While the UHTSS is being 
developed, Aurora is using prototype 
versions for the screening of -10,000 
single compounds a day, using 
standard 96-well plates. Already the 
throughput is high enough to 
dispense with the complications of 
compound mixtures. “Mixtures 
seemed like a good idea early on [in 
the history of combinatorial 
chemistry],” says Foulkes, “but by 
the time you can screen as fast as we 
can, single compounds make a lot 
more sense.” 
The collaboration game 
Packard is far from Aurora’s only 
collaborator. Foulkes is seeking four 
or five partners to share the cost and 
benefits of the UHTSS, and so far 
Bristol-Myers Squibb and Eli Lilly 
and Co. have signed up. “No one 
company could develop an equivalent 
system for the cost that it takes to be 
part of the consortium,” he says. 
In the meantime, other help is 
coming from all over: discrete- 
compound combinatorial libraries 
from Alanex Corp. and Arqule, Inc.; 
drug targets from genomics 
companies Sequana Therapeutics, 
Inc. and Allelix Biopharmaceutical 
Inc.; robotics from Carl Creative; and 
storage and retrieval systems from 
Universal Technologies, Inc. 
This multipartner marriage will 
need a lot of care and attention 
before profits start flowing. But if 
UHTSS becomes the screening 
method of choice, the payoff will 
be enormous. 
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